PMV Pharmaceuticals GAAP EPS of -$0.40

* PMV Pharmaceuticals press release [https://seekingalpha.com/pr/20303656-pmv-pharmaceuticals-reports-third-quarter-2025-financial-results-and-corporate-highlights] (PMVP [https://seekingalpha.com/symbol/PMVP]): Q3 GAAP EPS of -$0.40.
*
PMV Pharma ended the third quarter with $129.3 million in cash, cash equivalents, and marketable securities, compared to $148.3 million as of June 30, 2025. Net cash used in operations was $56.4 million for the nine months ended September 30, 2025, compared to $34.6 million for the nine months ended September 30, 2024.

MORE ON PMV PHARMACEUTICALS

* PMV Pharmaceuticals, Inc. (PMVP) Presents at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Slideshow [https://seekingalpha.com/article/4833392-pmv-pharmaceuticals-inc-pmvp-presents-at-aacr-nci-eortc-international-conference-on-molecular]
* PMV Pharmaceuticals, Inc. (PMVP) Special Call - Slideshow [https://seekingalpha.com/article/4822329-pmv-pharmaceuticals-inc-pmvp-special-call-slideshow]
* Seeking Alpha’s Quant Rating on PMV Pharmaceuticals [https://seekingalpha.com/symbol/PMVP/ratings/quant-ratings]
* Historical earnings data for PMV Pharmaceuticals [https://seekingalpha.com/symbol/PMVP/earnings]
* Financial information for PMV Pharmaceuticals [https://seekingalpha.com/symbol/PMVP/income-statement]